UnitedHealth Group endured a challenging 2025, with its share price falling 34% after the unexpected exit of its longtime CEO and the emergence of a federal probe into its Medicare billing practices. The company also under‐estimated rising care costs and saw patients’ service utilization outpace forecasts, contributing to two consecutive quarterly earnings misses. These factors combined to damp investor confidence and left UnitedHealth trailing the broader S&P 500, which posted its third straight annual gain.

Since taking the reins in May, CEO Steve Hemsley commissioned an independent, company‐wide process review that affirmed the robustness of UnitedHealth’s operations while identifying targeted improvements. Management has exited underperforming plans, adjusted benefits to better align pricing and utilization, repriced key product lines, and accelerated deployment of artificial intelligence tools to streamline claims adjudication. These measures coincided with 12% revenue growth in the fourth quarter and prompted management to raise its full‐year earnings forecast from $14.65 to $14.90 per share.

UnitedHealth projects continued headwinds from recent federal cuts to Medicare Advantage revenue but anticipates solid earnings growth in 2026 and sustainable double-digit expansion beginning in 2027. Trading at roughly 17 times trailing earnings—well below its three-year historical multiple—the stock offers an entry point for investors comfortable with ongoing regulatory scrutiny. Given UnitedHealth’s leading market position, diversified Optum and insurance businesses, and management’s turnaround track record, the company presents a compelling recovery story for patient, long-term shareholders.